Phase 2 MMY2002 trial of daratumumab in patients with at least 3 lines of prior therapy or double refractory multiple myeloma | Dr María-Victoria Mateos at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the results of the phase 2 MMY2002 trial of the anti-CD38 monoclonal antibody, daratumumab, in patients with at least 3 lines of prior therapy or double refractory multiple myeloma.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews